Estrogen replacement therapy lowers plasma levels of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase

2002 ◽  
Vol 3 (2) ◽  
pp. 216
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Synthase ◽  
Replacement Therapy ◽  
Plasma Levels ◽  
Estrogen Replacement Therapy ◽  
Asymmetric Dimethylarginine ◽  
Endogenous Inhibitor ◽  
Estrogen Replacement ◽  
Oxide Synthase

Indirect evidence that estrogen replacement therapy stimulates nitric oxide synthase in postmenopausal women

2000 ◽  
Vol 14 (2) ◽  
pp. 142-146 ◽  
Author(s):  
F. Piccinini ◽  
L. Rovati ◽  
A. Zanni ◽  
A. Cagnacci ◽  
A. Volpe ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Synthase ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Estrogen Replacement Therapy ◽  
Indirect Evidence ◽  
Estrogen Replacement ◽  
Oxide Synthase

scholarly journals Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension

2009 ◽  
Vol 296 (2) ◽  
pp. R195-R200 ◽  
Author(s):  
Dan Wang ◽  
Svend Strandgaard ◽  
Jens Iversen ◽  
Christopher S. Wilcox
Keyword(s):  
Oxidative Stress ◽  
Nitric Oxide ◽  
Blood Pressure ◽  
Essential Hypertension ◽  
Nitric Oxide Synthase ◽  
Plasma Levels ◽  
Asymmetric Dimethylarginine ◽  
Lipid Peroxidation Product ◽  
Individual Values ◽  
Oxide Synthase

We reported impaired endothelium-derived relaxation factor/nitric oxide (EDRF/NO) responses and constitutive nitric oxide synthase (cNOS) activity in subcutaneous vessels dissected from patients with essential hypertension ( n = 9) compared with normal controls ( n = 10). We now test the hypothesis that the patients in this study have increased circulating levels of the cNOS inhibitor, asymmetric dimethylarginine (ADMA), or the lipid peroxidation product of linoleic acid, 13-hydroxyoctadecadienoic acid (HODE), which is a marker of reactive oxygen species. Patients had significantly ( P < 0.001) elevated (means ± SD) plasma levels of ADMA (PADMA, 766 ± 217 vs. 393 ± 57 nmol/l) and symmetric dimethylarginine (PSDMA: 644 ± 140 vs. 399 ± 70 nmol/l) but similar levels of l-arginine accompanied by significantly ( P < 0.015) increased rates of renal ADMA excretion (21 ± 9 vs. 14 ± 5 nmol/μmol creatinine) and decreased rates of renal ADMA clearance (18 ± 3 vs. 28 ± 5 ml/min). They had significantly increased plasma levels of HODE (PHODE: 309 ± 30 vs. 226 ± 24 nmol/l) and renal HODE excretion (433 ± 93 vs. 299 ± 67 nmol/μmol creatinine). For the combined group of normal and hypertensive subjects, the individual values for plasma levels of ADMA and HODE were both significantly ( P < 0.001) and inversely correlated with microvascular EDRF/NO and positively correlated with mean blood pressure. In conclusion, elevated levels of ADMA and oxidative stress in a group of hypertensive patients could contribute to the associated microvascular endothelial dysfunction and elevated blood pressure.

Effect of asymmetric dimethyl arginine on nitric oxide synthase activity in normal and pre-eclamptic placentae

1995 ◽  
Vol 7 (6) ◽  
pp. 1581 ◽  
Author(s):  
RG King ◽  
Iulio JL Di ◽  
NM Gude ◽  
SP Brennecke
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Synthase ◽  
Asymmetric Dimethylarginine ◽  
Ion Exchange Chromatography ◽  
Exchange Chromatography ◽  
Endogenous Inhibitor ◽  
Asymmetric Dimethyl Arginine ◽  
Dimethyl Arginine ◽  
Oxide Synthase ◽  
Nitric Oxide Synthase Activity

An endogenous inhibitor of nitric oxide synthase (NOS), NG,NG dimethylarginine (asymmetric dimethylarginine, ADMA), which is present in human plasma and urine, has been reported to be elevated in the plasma of women with pre-eclampsia. As ADMA inhibition may contribute to reduced placental NOS activity observed in pre-eclampsia, the aim of this study was to compare the effects of ADMA on placental NOS activity from pre-eclamptic and normal pregnancies (gestational ages 38.4 +/- 0.9 and 38.3 +/- 0.3 weeks respectively). NOS activity was determined by measuring the conversion of [3H]L-arginine to [3H]L-citrulline in homogenates of normal and pre-eclamptic placentae in the absence and presence of increasing concentrations of ADMA (1-100 microM). The IC50 for ADMA for the pre-eclamptic placentae (22.1 +/- 2.1 microM, n = 6) was not significantly different from that for the normal placentae (18.8 +/- 1.4 microM, n = 6). When ADMA and L-arginine in homogenates was removed by ion exchange chromatography and exogenous L-arginine replaced (32 microM), the IC50 for the pre-eclamptic placentae (19.5 +/- 1.8 microM, n = 6) was not significantly different than that for the normal placentae (20.9 +/- 1.0 microM, n = 6), and NOS activity in the absence of endogenous and exogenous ADMA was still reduced in pre-eclamptic placentae. These results provide no evidence that the sensitivity of placental NOS to ADMA is affected by pre-eclampsia, or that placental ADMA contributes to the reduction of placental NOS in pre-eclampsia.

scholarly journals Plasma Concentration of Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Is Elevated in Monkeys With Hyperhomocyst(e)inemia or Hypercholesterolemia

2000 ◽  
Vol 20 (6) ◽  
pp. 1557-1564 ◽  
Author(s):  
Rainer H. Böger ◽  
Stefanie M. Bode-Böger ◽  
Karsten Sydow ◽  
Donald D. Heistad ◽  
Steven R. Lentz
Keyword(s):  
Nitric Oxide ◽  
Plasma Concentration ◽  
Nitric Oxide Synthase ◽  
Asymmetric Dimethylarginine ◽  
Endogenous Inhibitor ◽  
Oxide Synthase

Impact of Catheter Arteriography on the Serum Level of Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase

2008 ◽  
Vol 31 (3) ◽  
pp. 490-495 ◽  
Author(s):  
Ugur Bozlar ◽  
Mehmet Sahin Ugurel ◽  
Omer Ozcan ◽  
Erdinc Cakir ◽  
Bahri Ustunsoz ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Synthase ◽  
Serum Level ◽  
Asymmetric Dimethylarginine ◽  
Endogenous Inhibitor ◽  
Oxide Synthase
Sign in / Sign up

Export Citation Format

Share Document